Mrs. Diana Rita Hieb Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 N. Bradford Ave., West Chester, PA 19380 Phone: 610-696-0145 |
Dr. Hetal Chudasama, PHARM.D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 2709 Whittleby Ct, West Chester, PA 19382 Phone: 215-852-2528 |
Dr. Ralph Edward Cameron, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 550 E Union St, West Chester, PA 19382 Phone: 866-824-6337 |
Anitha Bhogi, B.PHARM Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1395 E Boot Rd, West Chester, PA 19380 Phone: 610-738-8870 Fax: 610-738-9082 |
Ms. Revathi Subramony, RPH CIP Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1395 E Boot Rd, West Chester, PA 19380 Phone: 610-738-8870 |
Dr. Brian J. Catton, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 300 N Bradford Ave, West Chester, PA 19380 Phone: 610-696-0145 |
Dr. Natalie Fosco, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1375 E Boot Rd, West Chester, PA 19380 Phone: 610-241-1061 |
Michael A Torosian, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1013 Ashley Rd, West Chester, PA 19382 Phone: 610-291-0703 |
Ms. Uma Surekha Sharma, R.PH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1501 Paoli Pike, West Chester, PA 19380 Phone: 610-692-6105 |
News Archive
Most ovarian cancer patients are diagnosed with late stage disease that is unresponsive to existing therapies. In a new study, researchers from the Perelman School of Medicine at the University of Pennsylvania School of Medicine show that a two-step personalized immunotherapy treatment - a dendritic cell vaccine using patients' own tumor followed by adoptive T cell therapy - triggers anti-tumor immune responses in these type of patients.
For every extra benefit Congress has required health insurers to provide, there is an extra cost. Ultimately, we all will pay the cost of these "free" services in the form of lower wages, higher taxes or higher health insurance premiums.
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.
RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego, Health Sciences as the second site for its upcoming phase I/II first-in-man trial for TT-034 in Hepatitis C infections.
› Verified 3 days ago